Alessa Therapeutics
regcellbio.com
Actively hiring
Higher Education
Health Care
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$15M
1 round on record
Latest round
$15M
Seed · Dec 2024 · 21 mo ago
Backers
4
Global Brain, Kyoto University Innovation Capital
The money's age
Due for its next round
21 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Seed | Dec 2024 | $15M | — | Pulse 2.0 |
Backed byfrom the funds' portfolios and accelerator catalogs
Global Brain 
Kyoto University Innovation Capital 
LG Technology Ventures 
UTEC Similar startupsby what they do, their industry and backers
0 About ZYGOFIX ZygoFix was founded by renowned orthopedic experts and enterpreneurs with a mission to transform joint stabilization and…
Restoring Blood Flow, Renewing Life. Creating new vascular pathways through targeted cell therapy and biomaterial engineering.
Shinobi Therapeutics is transforming cell therapy with scalable, immune-evasive iPSC-derived treatments for cancer and autoimmune diseases.
Promising and Ultimate RNA Medicine. Aiming innovative nucleic acid drugs that cure patients.
On a mission to transform the future of autoimmune care. Developing innovative therapies with the potential to redefine the standard of…
SurgeCare leverages immune profiling and AI to reveal early immune signatures and drive better decisions in surgery, trauma, infection, and…
News
Regcell adds $66M to take Nobel-winning Tregs to clinic
Regcell Inc. has raised $66 million in new financing and Japanese government support to move its Nobel-linked regulatory T-cell (Treg) platform toward the clinic, advancing an epigenetic reprogramming approach designed to convert disease-driving immune ce
Read more
Report
RegCell banks $66m to advance Nobel-winning immune tolerance platform
RegCell has closed a $66 million funding round combining a fully subscribed $44 million Series A financing and a $22 million non-dilutive grant from Japan's AMED.
Read more
Report
RegCell Secures $66 Million of Additional Funding to Bring Nobel-Winning Immune Tolerance Science to the Clinic
Combined financing will enable IND submission and advance RegCell's next-generation epigenetic reprogramming platform into a second autoimmune indication through Phase 2 as proof of concept. Read more here The post RegCell Secures $66 Million of Additiona
Read more
Report
RegCell Secures $66 Million of Additional Funding to Bring Nobel-Winning Immune Tolerance Science to the Clinic
RegCell today announced the publications of two studies inScience Translational Medicinefrom its scientific founder and member of its Board of Directors, Shimon Sakaguchi, MD, Ph.D., demonstrating, for the first time, the production of stable, antigen-spe
Read more
Report
Alessa Therapeutics Announces Enolen Phase 1 Study Presentation Receives
Alessa Therapeutics Announces Enolen Phase 1 Study Presentation Receives
Read more
Report
Reprogramming T Cells And Reducing Manufacturing Costs With RegCell's Michael McCullar, Ph.D.
In this episode of "Better Biopharma," host Tyler Menichiello speaks with Michael McCullar, Ph.D., CEO at RegCell, a cell-therapy company developing regulatory T cell (Treg) therapies for autoimmune diseases. They discuss RegCell's origins and its disease
Read more
Report
Cell Therapy Leverages Power of Regulatory T-Cells to Target Root Cause of Autoimmune Diseases with Dr. Mike McCullar RegCell
Dr. Mike McCullar, CEO of RegCell, is developing a novel cell therapy to treat autoimmune diseases that specifically addresses the loss of tolerance, in which the immune system mistakenly attacks the body's own tissues. This approach contrasts with curren
Read more
Report
Kincell Bio Partners with RegCell to Advance Treg Cell Therapy Toward Clinical Trials
Kincell Bio has announced a new collaboration with RegCell, a biotechnology company developing an immune tolerance platform based on epigenetically reprogrammed regulatory T cells. Under the agreement, Kincell Bio will provide comprehensive CMC developmen
Read more
Report
From Discovery to Therapy: The Rise of Reprogrammed Tregs
Nobel Prize winner Shimon Sakaguchi, a pioneer in regulatory T cell (Treg) biology, discusses the path from early observations to reprogrammed cell therapies for autoimmune disease. Read more here The post From Discovery to Therapy: The Rise of Reprogramm
Read more
Report
Scrip Asks… What Does 2026 Hold For Biopharma? Part 4: R&D Innovation
Enthusiastic predictions from industry leaders for ongoing progress in obesity, oncology, immunology, neuroscience and more were supported by optimism for the potential of AI and other technological advances to enable breakthroughs in processes as well as
Read more
Report
Show more news
Financials
Total raised
$15M
Latest round
Seed
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Seed | 2024 | $15M | Details |